The A8 sdAb was used to substitute the CD19 targeting single-chain antibody fragment (scFv) in a CD19-CAR T construct (CTL019/Kymriah, Novartis), currently used in hematologic cancer therapy [40]. This evidence concerns the gene CD19 and hematopoietic and lymphoid cell neoplasm.